Sponsor Questions Must Be More Focused In FDA Meetings - CBER's Feigal
Executive Summary
Sponsors must bring focused questions to meetings with FDA if the drug development and review process is to move more quickly, Center for Biologics Evaluation & Research Deputy Director for Medical Affairs David Feigal, MD, said during an FDA/Drug Information Association project management workshop on Oct. 14.